Kalaris Therapeutics closed at $2.10 on Nov 5, up 3.96%, 80.9% below its 52-week closing high. Volume of 80.2K shares was 1.19× its 20-day average (close to normal).
Split-adjusted performance: -18.0% over one month, -59.2% over six months, -55.4% over one year.
Short interest was 306.4K shares at the Oct 15 settlement, down 7.7% from the prior report (5.4% of float, 3.5 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KLRSKalaris Therapeutics | $2.10 | +3.96% | −59.2% | — | — | — | $50.0M | |
| GRMLGreenland Mines | $3.62 | −7.42% | — | — | — | — | $49.5M | Compare |
| ELOXEloxx Pharmaceuticals | $12.59 | −1.18% | — | — | — | — | $50.8M | Compare |
| INKTMiNK Therapeutics | $10.10 | −4.70% | −9.7% | — | — | — | $51.6M | Compare |
| TILInstil Bio | $6.97 | −0.29% | −13.2% | — | — | — | $47.3M | Compare |
| IMAImageneBio | $4.08 | −0.49% | −31.0% | — | — | — | $46.3M | Compare |
| CRBUCaribou Biosciences | $0.4069 | −8.44% | −78.4% | −43.8% | −1619.9% | — | $43.6M | Compare |
| CRDFCardiff Oncology | $0.7602 | −12.51% | −52.5% | −14.0% | −8882.7% | — | $59.1M | Compare |
| CGTXCognition Therapeutics | $0.6405 | −6.26% | −44.8% | — | — | — | $60.9M | Compare |
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
